Nivolumab
19-283
Phase 2 small_molecule terminated
Quick answer
Nivolumab for Relapsed Multiple Myeloma is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Relapsed Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated